Novel treatment strategies for hematological malignancies in the immunotherapy era
Author:
Open Access
- 11 June 2024
- journal article
- editorial
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (1) , 3-5
Abstract
The introduction of immunotherapies has led to remarkable progress in the treatment of hematological malignancies, including B-cell malignancies such as B-cell lymphoma and multiple myeloma (MM). Although conventional therapeutic antibodies are effective as immunotherapy for newly diagnosed and relapsed/refractory B-cell lymphoma and MM, some cases are resistant. Chimeric antigen receptor (CAR) T-cell therapies targeting B-cell lymphoma and MM have progressed through several generations, and have improved treatment strategies for relapsed/refractory disease. In addition to conventional therapeutic antibodies, bispecific antibodies targeting both tumor cells and T cells have been developed for MM. Both CAR T-cell therapies and bispecific antibodies are effective for heavily treated patients with relapsed/refractory disease. However, most patients treated with these therapies relapse, and serious adverse events like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are problematic. This Progress in Hematology, “Novel treatment strategies for hematological malignancies in the immunotherapy era,” focuses on such limitations and the future outlook for CAR T-cell therapies and bispecific antibodies for B-cell malignancies. The role of NK cells in anti-tumor immunity for AML and various therapeutic strategies for NK-cell therapy in AML is also discussed.Keywords
This publication has 31 references indexed in Scilit:
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical ExperienceAdvances in Therapy, 2017
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer ImmunotherapyClinical Cancer Research, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Loss of CD155 expression predicts poor prognosis in hepatocellular carcinomaHistopathology, 2014
- Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinomaHuman Pathology, 2014
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood, 2009
- NK cells and cancer immunosurveillanceOncogene, 2008
- Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamilyCell, 1989